Trial · NCT02510001
Results by group173
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 173
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 | Dose Escalation Phase Cohort 1 Dose Level 1 | 0 | Dose Limiting Toxicities (DLTs) | ||
| Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 | Dose Escalation Phase Cohort 2 Dose Level 2 | 0 | Dose Limiting Toxicities (DLTs) | ||
| Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 | Dose Escalation Phase Cohort 3 Dose Level 3 | 0 | Dose Limiting Toxicities (DLTs) | ||
| Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 | Dose Escalation Phase Cohort 4 Dose Level 4 | 1 | Dose Limiting Toxicities (DLTs) | ||
| Clinical Response to Binimetinib Combined With PF-02341066 | Dose Expansion Phase | Stable Disease | 7 | Participants | |
| Clinical Response to Binimetinib Combined With PF-02341066 | Dose Expansion Phase | Progressive Disease | 22 | Participants | |
| Clinical Response to Binimetinib Combined With PF-02341066 | Dose Expansion Phase | Early death from malignant disease | 1 | Participants | |
| Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066 | Dose Escalation Phase Cohort 7 Dose Level 5 | 2 | Dose Limiting Toxicities (DLTs) | ||
| Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066 | Dose Escalation Phase Cohort 12 Dose Level 5 (Interval Dosing) | 2 | Dose Limiting Toxicities (DLTs) | ||
| Maximal Tolerated Dose (MTD) of Binimetinib and PF-02341066 | Dose Escalation Phase Cohort 13 Dose Level 5a | 1 | Dose Limiting Toxicities (DLTs) | ||
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 1. | Summary PD-0325901 PK Day -1 | 77.8 | Standard Deviation 41.9 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 2. | Summary PD-0325901 PK Day -1 | 129 | Standard Deviation 50.5 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 3. | Summary PD-0325901 PK Day -1 | 226 | Standard Deviation 66.1 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 4. | Summary PD-0325901 PK Day -1 | 484 | Standard Deviation 84.1 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 1. | Summary PD-0325901 PK Day 21 | 70.3 | Standard Deviation 43.1 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 2. | Summary PD-0325901 PK Day 21 | 62.3 | Standard Deviation 34.7 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 3. | Summary PD-0325901 PK Day 21 | 135 | Standard Deviation 36.2 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 4. | Summary PD-0325901 PK Day 21 | 219 | Standard Deviation 93.6 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 1. | Summary PD-0315209 PK Day -1 | 53.1 | Standard Deviation 30.7 | ng/ml |
| Pharmacokinetic Peak Plasma Concentration (Cmax) for PF-02341066 and PD-0325901. | Dose Escalation Phase Dose 2. | Summary PD-0315209 PK Day -1 | 59.4 | Standard Deviation 35.3 | ng/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02510001/results